ArticleFrontiers in oncology2025
Interpretable multiparametric MRI radiomics-based machine learning model for preoperative differentiation between benign and malignant prostate masses: a diagnostic, multicenter study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A machine learning approach to predict treatment response in myofascial pain patients receiving masseter trigger point injections.BMC oral health · 2026Article
- Artificial intelligence in prostate biopsy: diagnostic applications, risk stratification, and precision oncology.Frontiers in oncology · 2026Review
- Interpretable machine learning models based on multi-dimensional fusion data for predicting positive surgical margins in robot-assisted radical prostatectomy: a retrospective study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study aimed to develop and externally validate multiparametric MRI (mpMRI) radiomics-based interpretable machine learning (ML) model for preoperative differentiating between benign and malignant prostate masses. Methods: Patients who underwent mpMRI with suspected malignant prostate masses were retrospectively recruited from two independent hospitals between May 2016 and May 2023. The prostate mass regions in T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) MRI images were segmented by ITK-SNAP. PyRadiomics was utilized to extract radiomic features. Inter- and intraobserver correlation analysis, t-test, Spearman correlation analysis, and the least absolute shrinkage and selection operator (LASSO) algorithm with a five-fold cross-validation were applied for feature selection. Five ML learning models were built using the chosen features. Model performance was evaluated with internal and external validation, using area under the curve (AUC), calibration curves, and decision curve analysis to select the optimal model. The interpretability of the most robust model was conducted via SHapley Additive exPlanation (SHAP). Results: A total of 567 patients were enrolled, consisting of the training (n = 352), internal test (n = 152), and external test (n = 63) sets. In total, 2,632 radiomic features were extracted from regions of interest (ROIs) of T2WI and DWI images, which were reduced to 18 via LASSO. Five ML models were established, among which the random forest (RF) model presented the best predictive ability, with AUCs of 0.929 (95% confidential interval [CI]: 0.885-0.963) and 0.852 (95% CI: 0.758-0.934) in the internal and external test sets, respectively. The calibration and decision curve analyses confirmed the excellent clinical usefulness of the RF model. Besides, the contributing relations of the radiomic features were uncovered using SHAP. Conclusions: Radiomic features from mpMRI combined with machine learning facilitate accurate preoperative evaluation of the malignancy in prostate masses. SHAP can disclose the underlying prediction process of the ML model, which may promote its clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.